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This study evaluated the tolerance and potential pharmacokinetic interactions between clarithromycin (500
mg every 12 h) and rifabutin (300 mg daily) in clinically stable human immunodeficiency virus-infected
volunteers with CD4 counts of <200 cells/mm3. Thirty-four subjects were randomized equally to either regimen
A or regimen B. On days 1 to 14, subjects assigned to regimen A received clarithromycin and subjects assigned
to regimen B received rifabutin, and then both groups received both drugs on days 15 to 42. Of the 14 regimen
A and the 15 regimen B subjects who started combination therapy, 1 subject in each group prematurely
discontinued therapy due to toxicity, but 19 of 29 subjects reported nausea, vomiting, and/or diarrhea.
Pharmacokinetic analysis included data for 11 regimen A and 14 regimen B subjects. Steady-state pharma-
cokinetic parameters for single-agent therapy (day 14) and combination therapy (day 42) were compared.
Regimen A resulted in a mean decrease of 44% (P 5 0.003) in the clarithromycin area under the plasma
concentration-time curve (AUC), while there was a mean increase of 57% (P 5 0.004) in the AUC of the
clarithromycin metabolite 14-OH-clarithromycin. Regimen B resulted in a mean increase of 99% (P 5 0.001)
in the rifabutin AUC and a mean increase of 375% (P < 0.001) in the AUC of the rifabutin metabolite
25-O-desacetyl-rifabutin. The usefulness of this combination for prophylaxis of Mycobacterium avium infections
is limited by frequent gastrointestinal adverse events. Coadministration of clarithromycin and rifabutin results
in significant bidirectional pharmacokinetic interactions. The resulting increase in rifabutin levels may explain
the increased frequency of uveitis observed with concomitant use of these drugs.
Mycobacterium avium complex (MAC) disease is a frequent
cause of morbidity and mortality in patients with late-stage
human immunodeficiency virus (HIV) infection (3, 4). In com-
mon with other mycobacterial infections, treatment of MAC
infections with combinations of drugs appears to be necessary
to improve efficacy and to prevent the emergence of resistance.
Clarithromycin and rifabutin are agents commonly used for
both the treatment and the prophylaxis of MAC infection.
Clarithromycin is a macrolide antibiotic with a high level of
activity against MAC, with MICs at which 90% of isolates are
inhibited (MIC90s) reportedly ranging between 1 and 4 mg/ml
for clinical isolates (2, 17, 19). MAC strains isolated from
patients without previous macrolide therapy are uniformly
susceptible to clinically achievable clarithromycin levels. A
dose-ranging, single-agent-treatment trial of clarithromycin
demonstrated impressive clinical activity in the reduction or
elimination of MAC bacteremia (8). The MIC90s of rifabutin
range between 0.25 and 2 mg/ml, although typically #60% of
the strains are susceptible to the drug at levels obtained with
present dosing practices (18, 37). The 25-O-desacetyl metabo-
lite of rifabutin has in vitro activity similar to that of rifabutin
(41). Rifabutin was effective for MAC prophylaxis in a place-
bo-controlled, double-blind trial (31). The combination of ri-
fabutin and clarithromycin was found to have additive activity
in vitro (23, 26) in macrophages (27) and the beige mouse
model (24).
Clarithromycin is a known inhibitor (22) and rifabutin is a
known inducer (5) of hepatic microsomal cytochrome P-450
enzymes. The effect of enzyme inhibition by clarithromycin
appears with the first dose, but it is not maximized until after
several doses (15). Enzyme induction by rifabutin was demon-
strated at 7 days by the increased metabolism of antipyrine
(32), and autoinduction of rifabutin metabolism was detected
at 10 days in studies with healthy volunteers (28). Pharmaco-
kinetic interactions between clarithromycin and rifabutin could
cause significant changes in the systemic exposure of both
parent compounds and their primary metabolites and could
have important implications for the safety and effectiveness of
therapy against MAC. In a group of patients treated with
clarithromycin for lung disease due to MAC, mean levels of
clarithromycin were decreased in those also receiving rifabutin
at 600 mg/day, indicating that this dosage of rifabutin appeared
* Corresponding author. Mailing address: Division of AIDS,
NIAID, 6003 Executive Blvd., Room 2B35, Rockville, MD 20852-7620.
Phone: (301) 402-2304. Fax: (301) 402-3171. E-mail: rh23v@nih.gov.
† Study DATRI 001 of the Division of AIDS Treatment Research
Initiative.
631
to induce clarithromycin metabolism (43). This study was de-
signed to evaluate the tolerance of combination therapy and
the potential pharmacokinetic interactions between clarithro-
mycin and rifabutin in a population with late-stage HIV infec-
tion.
MATERIALS AND METHODS
Subjects. Thirty-four clinically stable HIV-infected adult volunteers provided
written, informed consent according to the institutional guidelines of the partic-
ipating centers prior to enrollment. Patients were excluded for known MAC
bacteremia or a compatible syndrome, CD4 counts of .200 cells/mm3, acute
opportunistic infection or malignancy, a serum creatinine level of .2.0 mg/dl, a
bilirubin level of .2.0 mg/dL, aspartate aminotransferase and alanine amino-
transferase levels more than five times the upper limit of normal, a history of
sensitivity or intolerance to the study drugs, or recent use of clarithromycin
(within 14 days) or rifabutin (within 30 days). Patients requiring drugs likely to
interact pharmacokinetically with the study agents were excluded, with the ex-
ception that azoles for acute treatment or maintenance therapy for fungal infec-
tions were permitted.
Study design. Volunteers were randomized equally to one of two regimens.
Regimen A consisted of clarithromycin, at 500 mg every 12 h for 2 weeks (days
1 to 14), followed by a combination of the same clarithromycin dose plus rifabu-
tin, 300 mg once daily for an additional 4 weeks (days 15 to 42). Regimen B used
the same doses of study drugs used for regimen A, but the subjects received
rifabutin during days 1 to 14 and the combination of rifabutin and clarithromycin
during days 15 to 42. Subjects were instructed to take the daily rifabutin dose
with the morning dose of clarithromycin. Clinical evaluations and hematologic
and biochemical profiles were repeated every 2 weeks over an 8-week period,
with the last study visit occurring 2 weeks after the discontinuation of study
drugs. To monitor compliance, missed doses were self-reported by the study
participants. Subjects experiencing a possible drug-related toxicity of grade 3 or
higher, as defined by the Division of AIDS Table for Grading Severity of Adult
Adverse Experiences, were permanently discontinued from study therapy and
were followed until the resolution of the toxicity.
Pharmacokinetic sampling occurred on day 14, the time at which steady state
for either clarithromycin alone (regimen A) or rifabutin alone (regimen B) is
presumed to occur, day 15 (day 1 of combination therapy), and day 42 (presumed
combination steady state). Subjects fasted for 12 h before and 2 h after study
drug administration, but they were allowed water and concomitant medications.
For subjects receiving regimen A, blood was obtained predosing and at 0.25, 0.5,
0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 h after dosing on days 14 and 15. For days 42 and
43, blood was also obtained at hours 16, 24, 36, and 48. For subjects receiving
regimen B, blood was obtained predosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16,
and 24 h after dosing on days 14 and 15. For days 42 to 45, blood was also
obtained at hours 36, 48, 72, and 96. At weeks 3, 4, and 5, blood was obtained
within 1 hour prior to the administration of the next dose of combination study
medication for determination of trough levels. Blood samples for drug level
assays were centrifuged within 1 h of collection, and the plasma was aliquotted
and frozen at 270°C until it was assayed.
Study drugs. Clarithromycin was provided as 500-mg tablets by Abbott Lab-
oratories (Abbott Park, Ill.), and rifabutin was provided as 150-mg capsules by
Adria Laboratories (currently Pharmacia & Upjohn, Kalamazoo, Mich.).
Drug assays. The concentrations of the drugs in plasma were determined by
validated high-pressure liquid chromatographic techniques (10, 25). The concen-
trations of clarithromycin and 14 (R)-hydroxyclarithromycin (14-OH-clarithro-
mycin) in plasma were determined by Harris Laboratories (Lincoln, Nebr.);
rifabutin and 25-O-desacetyl-rifabutin concentrations in plasma were determined
by BAS Analytics (West Lafayette, Ind.).
The clarithromycin assay had a sensitivity of 0.0156 mg/ml and was linear from
0.0156 to 8.00 mg/ml. The between-day percent coefficients of variation were
10.1% at 0.0606 mg/ml, 10.7% at 0.25 mg/ml, and 6.4% at 2.00 mg/ml. The
sensitivity and linearity range were the same for 14-OH-clarithromycin. For this
metabolite, the between-day percent coefficients of variation of assay were 5.1%
at 0.065 mg/ml, 10.9% at 0.25 mg/ml, and 9.5% at 2.00 mg/ml.
The rifabutin and 25-o-desacetyl-rifabutin assays each required two standard
curves. Linearity was acceptable within each standard curve range. The rifabutin
low standard curve ranged from 0.005 to 0.060 mg/ml and the high standard curve
ranged from 0.060 to 0.800 mg/ml. The between-day percent coefficients of
variation for rifabutin were 17.4% at 0.00726 mg/ml, 10.8% at 0.029 mg/ml, 9.82%
at 0.144 mg/ml, and 8.2% at 0.726 mg/ml. For the 25-o-desacetyl-rifabutin me-
tabolite, the low standard curve ranged from 2.5 to 30 ng/ml and the high
standard curve ranged from 30 to 400 ng/ml. The between-day percent coeffi-
cients of variation for 25-o-desacetyl-rifabutin were 19.7% at 0.00319 mg/ml,
12.0% at 0.0127 mg/ml, 10.9% at 0.0634 mg/ml, and 12.1% at 0.319 mg/ml.
Statistical considerations. It was projected that a sample of 12 evaluable
subjects would provide at least an 80% power (with a 5 0.05) for one-sided tests
of the hypothesis that combination therapy would be tolerated by 67% or more
of the subjects receiving each regimen against the alternative that only 33% could
tolerate the therapy. The baseline characteristics of the subject groups were
compared by the Student t test and the chi-square test. The study was also
designed to determine if apparent drug clearance for each agent, as measured by
the mean change in the area under the plasma concentration-time curve (AUC),
would be significantly modified in the presence of the other drug.
The LAGRAN software of Rocci and Jusko (34) was used to compute AUC.
The maximal concentration (Cmax) and the time to Cmax (Tmax) were determined
by inspection of interpolated curves. lz, the terminal elimination rate constant,
was determined by fitting a log-linear regression to the data for the last four time
points of the terminal phase; in cases of a delayed Tmax, fewer points were used.
AUC0–t is the presumed steady-state value for each drug and its metabolite
during the period between doses. For day 15, the AUC0–` (the AUC from time
zero to infinity) of the drug initiated on that day was calculated as AUC0–Cn 1
Cn/lz, where Cn is the concentration at the last measurable time point. Treat-
ment arms were compared by two-sample t tests.
RESULTS
Subject characteristics. A total of 34 volunteers, 17 receiv-
ing each regimen, were enrolled into the study at six partici-
pating centers between 16 June 1992 and 27 October 1992.
Thirty-two subjects began the single-drug therapy to which
they were randomized, and 29 of these subjects initiated com-
bination therapy on day 15. Data for 11 volunteers randomized
to regimen A and 14 volunteers randomized to regimen B were
included in the pharmacokinetic analysis (Table 1).
The baseline characteristics of the 32 study volunteers who
started a study drug are presented in Table 2. At enrollment,
the mean CD4 cell counts were 67 and 82 cells/mm3 (P 5 0.25)
TABLE 1. Study enrollment, withdrawal, and completion ratesa
Subject characteristic
No. of subjects
Regimen A Regimen B Total
Subjects who were randomized 17 17 34
Subject withdrawal for acute illness before treatment with a single drug was initiated 1 1 2
Subjects evaluable for single-drug tolerance 16 16 32
Subject withdrawal of consent before two drug combination was initiated 1 1 2
Subject noncompliance before two-drug combination was initiated 1 0 1
Subjects evaluable for combination drug tolerance 14 15 29
Subject withdrawal for adverse event after two-drug combination was initiated 1 1 2
Subject noncompliance during two-drug combination 1 0 1
Subjects completing the study 12 14 26
Subjects for whom no pharmacokinetic data were available because of technical problems 1 0 1
Subjects for whom data were evaluable for pharmacokinetic analysis 11 14 25
a Regimen A, clarithromycin on days 1 to 14 and both study drugs on days 15 to 42; regimen B, rifabutin on days 1 to 14 and both study drugs on days 15 to 42.
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for regimen A subjects and regimen B subjects, respectively.
The only characteristic for which there was a significant differ-
ence at the baseline was weight (P 5 0.02), but there was no
significant difference in body surface area (P 5 0.13). There
were no statistically significant differences in the baseline char-
acteristics of the 26 subjects who completed the study com-
pared to those of the 6 subjects who did not complete the study
(data not shown).
Drug tolerance and adverse events. After 1 week of combi-
nation therapy, one regimen A subject experienced grade 3
myalgia and one regimen B subject experienced grade 3 leu-
kopenia; each subject discontinued the study drugs. The 95%
confidence intervals for the proportion tolerating combination
therapy are as follows: for regimen A subjects (13 of 14 sub-
jects), 80.7 to 99.6%; for regimen B subjects (14 of 15 subjects),
81.9 to 99.7%. In neither regimen was the hypothesis of at least
67% tolerance rejected (P $ 0.97).
Gastrointestinal (GI) symptoms were reported frequently,
with 19 of 29 (65.5%) subjects reporting nausea, vomiting, or
diarrhea events during combination therapy. All except three
of these GI events were grade 1; one subject had a single report
of grade 2 nausea (defined as four to five episodes per day or
vomiting for 1 week or longer) at week 1, and two others had
reports of grade 2 diarrhea (defined as five to seven loose
stools per day or nocturnal loose stools) at week 3. Of these 19
subjects, 9 had only one type of GI symptom (3 subjects had
nausea and 6 subjects had diarrhea) and 11 had multiple symp-
toms (5 subjects had nausea and diarrhea, 2 subjects had nau-
sea and vomiting, and 4 subjects had all three symptoms). The
GI complaints were persistent in 16 volunteers who reported
the same symptom on 2 or more consecutive weekly visits
during combination therapy. HIV-related conditions occurring
during the study included herpes simplex in 1 subject and oral
candidiasis in 12 subjects.
Effect of rifabutin on clarithromycin pharmacokinetics.
Data for three regimen A subjects who received combination
therapy were not used in the pharmacokinetics analysis; one
subject had poor study drug compliance, one subject prema-
turely withdrew from the study due to an adverse event, and
technical problems prevented the use of one subject’s samples.
Table 3 presents the estimated values of the pharmacokinetic
parameters, including the AUC0–12, Cmax, and Tmax of cla-
rithromycin and 14-OH-clarithromycin, for regimen A subjects
on days 14, 15, and 42. Figure 1 displays the AUCs of clar-
ithromycin (Fig. 1a) and 14-OH-clarithromycin (Fig. 1b) for
each of the three sampling periods.
The mean decrease in the clarithromycin AUC0–12 between
days 14 and 42 was 44% (P , 0.003) (Table 3). A significant
decrease was observed when comparing the mean clarithromy-
cin AUC0–12 between days 15 and 42 (P , 0.004) but not
between days 14 and 15 (P 5 0.678). The individual clarithro-
mycin AUC0–12 estimates decreased 23.4 to 83.5% between
days 14 and 42 for all except one subject; the AUC0–12 for one
subject increased by 49%. The mean increase in the 14-OH-
clarithromycin AUC0–12 between days 14 and 42 was 57% (P 5
0.004). The increase was also significant between days 15 and
42 (P 5 0.006) but not between days 14 and 15 (P 5 0.795).
The mean decrease in the clarithromycin Cmax between days
14 and 42 was 41% (P 5 0.003), and a significant decrease was
seen in the mean Cmax estimates between days 15 and 42 (P ,
0.008). The mean increase in the Cmax of the 14-OH-clarithro-
mycin metabolite between days 14 and 42 was 69% (P 5
0.001). No statistically significant changes were seen in the
Tmax of clarithromycin or the 14-OH-clarithromycin metabo-
lite among any of the three time points.
Effect of clarithromycin on rifabutin pharmacokinetics. One
regimen B subject who received combination therapy prema-
turely withdrew from the study due to an adverse event, and
data for that subject were not used in the pharmacokinetic
analysis. The AUC0–24, Cmax, and Tmax values for rifabutin and
25-O-desacetyl rifabutin on days 14, 15, and 42 for regimen B
subjects are presented in Table 4. Figure 2 displays the AUCs
of rifabutin (Fig. 2a) and 25-O-desacetyl rifabutin (Fig. 2b) for
each of the three sampling periods.
The mean increase in the rifabutin AUC0–24 between days
14 and 42 was 99% (P 5 0.001) (Table 4). Most of this change
occurred between days 14 and 15 (P , 0.001), while the change
between days 15 and 42 was not significant (P 5 0.152). The
individual rifabutin AUC0–24 estimates increased 19 to 266%
between days 14 and 42 for all except one subject; the AUC0–24
for one subject decreased by 39%. The mean increase in the
25-O-desacetyl rifabutin AUC0–24 between day 14 and day 42
was 375% (P , 0.001). This increase was also significant be-
tween days 14 and 15 (P 5 0.003) and between days 15 and 42
(P 5 0.002).
The mean increase in the rifabutin Cmax between days 14 to
42 was 69% (P 5 0.011). The changes in Cmax between days 14
and 15 and between days 15 and 42 were not significant (P $
0.20) because of the large variability in the Cmax estimate at
day 15 (Table 4). The mean increase in the Cmax for the
rifabutin metabolite between days 14 to 42 was statistically
significant (P 5 0.034). As also shown in Table 4, the mean
percent change in the rifabutin Tmax showed a significant in-
crease between days 14 and 42 (P 5 0.013). The mean percent
change in the 25-O-desacetyl rifabutin Tmax also increased
significantly between days 14 and 42 (P 5 0.017).
Concomitant medications. Ten subjects (five subjects from
each regimen) received an azole antifungal agent (fluconazole,
n 5 8; ketoconazole, n 5 2) for some period of time during
their participation in the study. For regimen A, the mean
TABLE 2. Baseline characteristics of the 32 subjects who started
study drugsa
Characteristic Regimen A(n 5 16)
Regimen B
(n 5 16)
Gender (no. of subjects)
Male 14 15
Female 2 1




HIV risk factors (no. of subjects)
Male homosexual or bisexual
contact(s)
12 12
Male homosexual or bisexual
contact(s) and intravenous drug use
2 1




Mean (SD) age (yr) 36.3 (8.0) 36.8 (7.8)
Mean (SD) wt (kg) 68.7 (10.3) 74.3 (8.2)
Mean (SD) body surface area (m2) 1.8 (0.2) 1.9 (0.1)
Mean (SD) CD4 cell count (cells/mm3) 67 (50) 82 (52)
a Regimen A, clarithromycin on days 1 to 14 and both study drugs on days 15
to 42; regimen B, rifabutin on days 1 to 14 and both study drugs on days 15 to 42.
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clarithromycin AUCs at day 14 were 37.1 and 36.1 mg z h/ml for
the subjects receiving azoles (n 5 4) and those not receiving
azoles (n 5 7), respectively. At day 42, the mean clarithromy-
cin AUCs were 17.8 and 15.6 mg z h/ml for the azole recipients
(n 5 5) and those not receiving azoles (n 5 6), respectively.
For regimen B, the mean rifabutin AUCs at day 14 were 3.8
and 4.4 mg z h/ml for the subjects receiving azoles (n 5 4) and
those not receiving azoles (n 5 10), respectively. At day 42, the
mean rifabutin AUCs for the azole recipients (n 5 5) and
those not receiving azoles (n 5 9) were 6.9 and 7.2 mg z h/ml,
respectively. For both regimens, these mean study drug AUCs
for patients receiving azoles compared to those for patients not
receiving azoles at both day 14 and day 42 were not signifi-
cantly different. The regimen A subject with an atypical AUC
response was receiving fluconazole throughout the study, and
the regimen B subject with an atypical AUC response did not
receive any azole therapy. Other concomitant medications in-
cluded zidovidine (23 subjects), ddI (14 subjects), dapsone (11
subjects), ddC (4 subjects), and trimethoprim-sulfamethox-
azole (7 subjects).
DISCUSSION
In 1992, plans for large randomized clinical trials were de-
veloped to optimize MAC prophylaxis by comparing the most
promising new therapies. One of these trials, trial ACTG 196/
CPCRA 009, was designed to compare clarithromycin, rifabu-
tin, and both drugs in combination. The combination arm was
included to determine if effectiveness could be increased by
preventing clarithromycin resistance, because relapses of MAC
bacteremia with macrolide-resistant strains occurred fre-
quently during a trial of clarithromycin alone for the treatment
of disseminated MAC disease (8). The tolerance of this com-
bination in the target population and the possibility of bidirec-
tional pharmacokinetic drug interactions were important is-
sues to be considered in the design and conduct of the ACTG/
CPCRA phase III prophylaxis trial. Trial DATRI 001A was
designed to address these questions directly with a population
of subjects with late-stage HIV infection.
The outcome of this study validated the hypothesis that
.67% of the volunteers could tolerate the combination of
clarithromycin and rifabutin over a total of 28 days. Only 2
(7%) of the 29 subjects receiving combination therapy discon-
tinued the study drugs due to toxicities, but adverse events
were frequently reported. Nineteen subjects (66%) reported
GI complaints of nausea, vomiting, and/or diarrhea during the
combination-therapy period. Given the relatively short period
of evaluation, the combination therapy may be much less well
tolerated over the longer term. Also, while these adverse
events were not serious and may be tolerated during treatment
of disseminated MAC infection, they may be less often toler-
ated during prophylaxis.
The single-drug pharmacokinetic profiles are consistent with
those from previous studies of HIV-negative and HIV-infected
subjects receiving single-agent therapy (9, 38, 42). Both phar-
macokinetic interactions demonstrated in this study were ex-
tensive, with the mean day 42 clarithromycin AUC0–12 decreas-
ing by 44% and the mean rifabutin AUC0–24 increasing by 99%
(P values for both comparisons, #0.003). These two-way phar-
macokinetic interactions between clarithromycin and rifabutin
are consistent with the ability of rifabutin to induce cla-
rithromycin metabolism and, conversely, the inhibitory effect
of clarithromycin on rifabutin metabolism. The observed time
course for the clarithromycin AUC0–12 reduction, which was
not appreciable at day 15 but which was highly significant at
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tion by rifabutin. The increase in the 14-OH-clarithromycin
AUC0–12 was also only apparent at day 42, further supporting
an enzyme induction mechanism. Rifabutin levels increased
significantly following the administration of a single clarithro-
mycin dose, and most of the change between days 14 and 42
(60%) occurred between days 14 and 15. This finding is con-
sistent with clarithromycin inhibition of enzyme metabolism.
The identity of the responsible enzymes is in question. While
evidence from one in vitro study indicates that CYP3A4 has a
major role (20), other evidence indicates that rifabutin is not
metabolized by CYP3A4 (39).
The mean percent increases in the 25-O-desacetyl-rifabutin
metabolite AUC0–24 observed between days 14 and 42 were
greater than the mean increases in the rifabutin AUC0–24 over
the same time periods, suggesting that the enzyme responsible
for conversion of rifabutin to the 25-O-desacetyl metabolite is
not inhibited. In addition, this finding also suggests that cla-
rithromycin inhibits conversion of the parent compound to
alternative primary metabolites and the further metabolism of
25-O-desacetyl-rifabutin (for example, by inhibiting conversion
of both the parent and 25-O-desacetyl forms to their 31-hy-
droxy metabolites) (11).
The data indicating decreased clarithromycin levels at day 42
were consistent among all except one of the regimen A sub-
jects; for one subject the clarithromycin AUC0–12 had in-
creased by 57% at day 42. The AUC change for this subject
cannot be explained by concomitant medications (i.e., flucon-
azole use predated study entry), but additional doses of cla-
rithromycin may have been taken. An increase in rifabutin
levels at day 42 was a consistent finding for all regimen B
subjects except one subject for whom the AUC decreased by
39%. The day 14, day 21, and day 42 trough levels for this
FIG. 1. Composite curves of mean clarithromycin concentrations (a) and 14-OH-clarithromycin concentrations (b) for regimen A subjects during the three
pharmacokinetic sampling periods. Regimen A was clarithromycin, 500 mg every 12 h during days 1 to 14 and then the same clarithromycin dose with rifabutin, 300
mg daily during days 15 to 42.
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subject were 0.144 mg/ml 0.341 mg/ml, and undetectable
(,0.050 mg/ml), respectively, suggesting decreased compliance
with the study drug regimen prior to the final pharmacokinetic
sampling session. Both subjects with atypical AUC changes
reported excellent compliance. These outlying results lessen
the magnitude of the pharmacokinetic interaction estimates
and suggest that the observed mean changes in AUC0–t are
conservative estimates. The day 42 AUC values for both the
drugs and the measured metabolites were not significantly dif-
ferent when the AUCs for subjects receiving regimen A (cla-
rithromycin initiated first) and those receiving regimen B (ri-
fabutin initiated first) were compared. This indicates that
steady-state values had been reached by day 42 and that the
order of addition of these drugs did not affect their pharma-
cokinetic disposition at steady state (all P values were $0.120);
i.e., no period effect was apparent.
There have been several reports of uveitis occurring in pa-
tients receiving rifabutin, usually at dosages of $450 mg/day
and often in combination with clarithromycin (13, 14, 30, 35,
36). Preliminary data from trial ACTG 196/CPCRA 009, a
randomized comparison of clarithromycin, rifabutin, and the
combination for prophylaxis of MAC infection, support a spe-
cific association of uveitis with this drug combination. In the
preliminary analysis of 1,178 eligible patients, uveitis occurred
in 23 patients initially assigned to the combination of clarithro-
mycin (500 mg twice daily) and rifabutin (450 mg daily, which
was later reduced to 300 mg daily) and in 5 patients assigned to
rifabutin and 2 patients assigned to clarithromycin at the same
doses (13). No episodes of uveitis were reported for volunteers
in the present study, but uveitis has been most commonly
reported after receiving at least 4 weeks of combination ther-
apy and appears to be very infrequent in patients receiving
rifabutin at dosages of #300 mg/day in combination with cla-
rithromycin.
The exact mechanism of this adverse event is unknown (30).
The possible relationship between the concentrations of the
parent compound and its metabolite in plasma and adverse
reactions, particularly uveitis and polyarthritis, require further
investigation. Previously, uveitis had been reported in subjects
receiving $1,800 mg of rifabutin alone in a dose-escalating
tolerance and pharmacokinetic study (36), suggesting that uve-
itis may be related to high concentrations of rifabutin or its
metabolites in plasma. If this hypothesis is correct, the in-
creased levels of rifabutin and its 25-O-desacetyl metabolite
occurring in the presence of clarithromycin, as documented by
this study, could explain the increased risk of uveitis associated
with combination therapy. Alternatively, but less likely, uveitis
may be due to increases in the levels of other rifabutin metab-
olites produced as a consequence of this pharmacokinetic in-
teraction or enhancement of a toxic rifabutin effect by clar-
ithromycin or its metabolites.
Only a small minority of the patients who receive combina-
tion therapy including rifabutin at dosages of less than 600 mg
and clarithromycin develop uveitis. Considerable intersubject
variability was noted in this study. The increase in the rifabutin
AUC0–24 was greater than 150% for 5 of the 14 regimen B
subjects, and for 2 of those the increase was greater than 200%.
Increases in the 25-O-desacetyl rifabutin AUC0–24 were
greater than 600% for three subjects. The patients experienc-
ing the most substantial increases in rifabutin and 25-O-
desacetyl rifabutin AUC0–24 values during combination therapy
may be at the highest risk for uveitis.
Antifungal azoles are a class of drugs likely to have signifi-
cant pharmacokinetic interactions with rifabutin and clarithro-
mycin. A pharmacokinetic interaction between rifabutin and
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be significantly increased in the presence of fluconazole, a
specific relationship between the concomitant use of azoles
and rifabutin and an increased risk of uveitis in the absence of
clarithromycin has not been established. It also remains to be
determined if the inhibitory effects of azoles and clarithromy-
cin on rifabutin metabolism are additive. The data for the study
volunteers who received azoles do not appear to differ from
those for the remaining subjects, but a formal assessment of
any additive effect was not possible. Whether concurrent ther-
apy with fluconazole and other azoles would also alter the
plasma concentration-time profile of clarithromycin or its me-
tabolites requires further study, given the frequent use of sys-
temic antifungal therapy in this population.
The decreased levels of clarithromycin could diminish the
expected clinical efficacy of combination therapy, because in
vitro studies supporting the increased activity of this combina-
tion did not take into account the observed decrease in cla-
rithromycin concentrations. If the decrease in clarithromycin
levels results in diminished clinical antimycobacterial activity,
the concurrent increase in the levels of the 14-OH-clarithro-
mycin metabolite will not provide significant compensatory
activity. The mean increase in the metabolite AUC0–12 was 4.3
mg z h/ml, while the mean decrease in the clarithromycin
AUC0–12 was 19.9 mg z h/ml. Also, the 14-hydroxy metabolite
is approximately eightfold less active than the parent com-
pound against MAC in vitro (19). To compensate for this
interaction, the dosage of clarithromycin could be increased
when it is used in combination with rifabutin. However, a
higher clarithromycin dosage could exacerbate GI intolerance
and may cause a further increase in the concentrations of
rifabutin and its metabolites, possibly resulting in a higher
incidence of uveitis. Furthermore, in treatment studies com-
paring the standard dosage of clarithromycin (500 mg twice
daily) with higher dosages of clarithromycin (either alone or in
FIG. 2. Composite curves of mean rifabutin concentrations (a) and 25-O-desacetyl rifabutin concentrations (b) for regimen B subjects during the three pharma-
cokinetic sampling periods. Regimen B was rifabutin, 300 mg daily during days 1 to 14 and then the same rifabutin dose with clarithromycin, 500 mg every 12 h during
days 15 to 42.
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combination regimens) for the treatment of disseminated
MAC, patients assigned to the higher-dose treatment arms had
poorer survival rates (8, 12). It is impossible to determine at
this time whether the pharmacokinetic interaction between
clarithromycin and rifabutin would have an effect on the
poorer survival rate. Until this is further defined, clarithromy-
cin either alone or in combination with rifabutin should not be
administered at a dosage of greater than 500 mg twice daily for
the treatment of MAC infection.
This study does not support the use of clarithromycin and
rifabutin in combination for MAC prophylaxis. Combination
of these drugs results in a high frequency of adverse events and
bidirectional pharmacokinetic interactions. The results of the
ACTG 196/CPCRA 009 study comparing clarithromycin, ri-
fabutin, and the combination for MAC prophylaxis indicated
that the use of the combination did not increase efficacy and
caused more toxicity compared to the use of clarithromycin
alone (13). The reduction of plasma clarithromycin levels due
to pharmacokinetic interaction with rifabutin is a possible ex-
planation for the lack of additional efficacy for this drug com-
bination. In contrast, a large randomized study comparing ri-
fabutin (300 mg/day), azithromycin (1,200 mg/week), and the
combination of both demonstrated that the azithromycin-con-
taining regimens were more effective than those containing
rifabutin alone and that the combination regimen was signifi-
cantly more effective than azithromycin alone for the preven-
tion of disseminated MAC infection (16). One explanation for
the enhanced effectiveness of azithromycin and rifabutin in
combination may be that azithromycin does not undergo me-
tabolism and therefore rifabutin does not reduce azithromycin
levels (1, 29). The investigators cautioned that use of the
azithromycin and rifabutin combination may be limited by its
significantly poorer tolerance and increased cost and rifabu-
tin’s pharmacokinetic interactions with medications commonly
used concomitantly (16). Considering the results of these trials,
monotherapy either with clarithromycin or with azithromycin
once weekly is recommended as first choice for MAC prophy-
laxis (7).
The introduction of protease inhibitors for HIV therapy has
led to additional concerns regarding the choice of drugs for
MAC prophylaxis. Rifabutin increases the metabolism of pro-
tease inhibitors (21), protease inhibitors significantly inhibit
rifabutin metabolism (6), and with concomitant use, adjust-
ment of the rifabutin dosage is necessary to prevent increased
adverse events (7, 21). While protease inhibitors inhibit the
metabolism of clarithromycin, the clinical significance of this
interaction is unknown, and dose adjustment is not advised (7,
33). Because azithromycin is not significantly metabolized
and is not known to inhibit the metabolism of other drugs,
pharmacokinetic interactions with the protease inhibitors are
unlikely (1, 29). The occurrence of clinically significant phar-
macokinetic interactions between rifabutin and protease inhib-
itors further support the use of clarithromycin or azithromycin
alone for MAC prophylaxis.
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